Business
MAIA Biotechnology Announces $1.08 Million Private Placement
CHICAGO, May 05, 2025--MAIA Biotechnology Announces $1.08 Million Private Placement
About this update from Maia Biotechnology, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1000,"height":380,"url":"https://media.zenfs.com/en/business-wire.com/214cb4fd05c601c8e1b974b0e25bb630"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZtxHXNYGBwbX6SAGNh42bg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM2NTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/214cb4fd05c601c8e1b974b0e25bb630","width":960,"height":365},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/vkLOhqk8kF1BLH3h7W0x6w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwMDA7aD03NjA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/214cb4fd05c601c8e1b974b0e25bb630","width":1000,"height":380}},"lazy":false},{"type":"text","content":"CHICAGO, May 05, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 719,999 shares of common stock at a purchase price of $1.50 per share, in a private placement to accredited investors and certain Company directors. Each share of common stock is being offered together with a warrant to purchase one share of common stock at an exercise price of $2.05 per share, which price represents the greater of the book or market value of the stock on the date the definitive agreements were executed (subject to customary adjustments as set forth in the warrants). The warrants are exercisable commencing six months following issuance and have a term of five years from the initial exercise date. The securities being sold to the Company directors participating in the offering are being issued pursuant to the Company’s 2021 Equity Incentive Plan. The private placement is expected to close on or about May 7, 2025, subject to the satisfaction of customary closing conditions.","length":1233,"tagName":"p"},{"type":"text","content":"The gross proceeds from the offering are expected to be approximately $1.08 million, prior to offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for to fund the starting cost for Part C of the Phase II trial THIO -101 and for working capital.","length":295,"tagName":"p"},{"type":"te...